Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
DISEASE
NETWORK
REGISTRY
PROJECTS
LOGIN
Experimental Rx
-
News
The Project
Sponsor
Executive Committee
Arnesen
Blumenstein
Burgunder
Craufurd
Humbert
Jones
Kremer
Reilmann
Roos
Rosser
Weydt
Capper-Loup
Feihle
Levey
McLean
Public Documents
Writing Committee Strategic ...
Dates
Scientific and Bioethics Advis...
Becanovic
Busse
Frontali
Giorgini
Holmans
Mariotti
Norremolle
Reetz
Rickards
Saft
van Duijn
Valenza
Verellen
Public Documents
Central Coordination
Language Coordination
Fellowship Programme
Constitution
Article 1
Article 2
Article 3
Article 4
Article 5
Article 6
Article 7
Article 8
Article 9
Article 10
Article 11
Article 12
Documents
Voting/Nomination
Members
Locations
Austria
Belgium
Czech Republic
Denmark
Finland
France
Germany
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Russia
Spain
Coordination
Meeting 2008
Meeting 2009
Meeting 2010
Meeting Documents
Meeting 2011
Meeting 2012
Meeting 2013
HD Associations
Alicante
Badajoz
Barcelona - Bellvitge
Barcelona - Clinic i Provincia...
Barcelona - Mutua de Terra...
Barcelona - Santa Creu i Sa...
Barcelona - Merced
Bilbao
Burgos
Canaries
Granada
Fuenlabrada
Madrid-BTCIEN
Madrid - Clínico
Madrid - FJD
Madrid - RyC
Murcia
Oviedo
Palma de Mallorca
Pamplona
Santiago
Sevilla
Sevilla-HUVRocio
Sevilla-St-Ana
Valencia
Zaragoza
Sweden
Switzerland
U.K.
Outside Europe
Working Groups
Events
EHDN 2016
EHDN 2014
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Pathogenic mechanisms
Animal models
Choreatic disorders - no...
Genetic modifiers
Wet Biomarkers
Imaging
Clin characteristics
Clin char-motor
Clin char-cognitive
Clin char - behaviour
Clin char-other
Clinical studies
Genetic testing
Clinical care
Experimental Rx
Clinical Rx
Non-scientific
Contacts
Feedback & Evaluation
EHDN 2010
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
EHDN 2004
Communication
Contact Form
Chat Rooms
Mailinglists - public
Newsletter
Job Offers
datum
description
size
author
document
04.08.26
In vivo efficacy of (CUG)n oligonucleotides to treat HD
32 kB
anonymous
p02-in-vivo-efficacy-oligonucleotides
04.08.26
Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease
32 kB
anonymous
p01-antisense-oligonucleotide-transcript
04.08.26
Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping
32 kB
anonymous
p03-exon-skipping
04.08.26
A Huntingtin peptide inhibits polyQ-hHtt associated defects
32 kB
anonymous
p04-polyq-hhtt-associated-defects
04.08.26
Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy
32 kB
anonymous
p07-glatiramer-acetate
04.08.26
Olesoxime improves specific features of the HD pathology
32 kB
anonymous
p06-olesoxime
04.08.26
Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!
32 kB
anonymous
p08-analysis-of-nrf2
Folder contains 7 documents.
about us
|
privacy statement
|
disclaimer
|
terms of use